RET fusion-positive NSCLC patients benefit from targeted therapies like Retevmo and Gavreto, recommended by NCCN guidelines for first-line treatment. Gavreto demonstrated a 57% overall response rate ...
The treatment of metastatic colorectal cancer (mCRC) remains challenging. There has been substantial progress in understanding the molecular pathology of the disease that has led to meaningful ...
Panelists discuss how quadruplet regimens show improved efficacy over triplet regimens without significantly increased safety concerns, with anti-CD38 antibodies being well tolerated and NCCN ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback